News | February 11, 2022
Marksans Pharma Q3FY22 PAT at Rs. 48.27 crore
Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021
Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021
It is being developed by Pune-based Gennova Biopharmaceuticals
GOSTAR's proprietary data set underwent rigorous analysis and large-scale ML model building to predict drug solubility in a recent joint study. X-Chem's RosalindAI delivered superior and actionable results than other similar analyses using well-known publically available datasets
Urban, semi-urban and remote corners of the country will be catered using drone delivery technology
MedleyMed is present across the pharma and healthcare value chain. It offers digital solutions to all stake holders and is in the process of expanding its operations in India and USA. In an interview with Thomas C Thottathil, M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed discussed his plans and opportunities in India
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Granules India has reported consolidated financial results for the period ended December 31, 2021
Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
